Madrigal Pharmaceuticals Inc

NASDAQ:MDGLUnited States

Yesterday

Show headlines and story abstract

• Madrigal Pharmaceuticals Reports Positive Results in New Analysis of Phase 3 Trial of NASH Drug Rezdiffra, from 9:39AM ET on Thursday Jun 06, 2024 by MT Newswires

  9:39AM ET on Thursday Jun 06, 2024 by MT Newswires
  Companies Mentioned: MDGL
  09:39 AM EDT, 06/06/2024 (MT Newswires) -- Madrigal Pharmaceuticals (MDGL) said Thursday that a new analysis of its phase 3 trial MAESTRO-NASH Rezdiffra trial showed that the treatment "improved key fibrotic features that are predictive of progressi...

• Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra(TM) (resmetirom) Presented at the EASL Congress, from 8:00AM ET on Thursday Jun 06, 2024 by GlobeNewswire

  8:00AM ET on Thursday Jun 06, 2024 by GlobeNewswire
  Companies Mentioned: MDGL

• Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra(TM) (resmetirom) Presented at the EASL Congress, from 8:00AM ET on Thursday Jun 06, 2024 by Dow Jones

  8:00AM ET on Thursday Jun 06, 2024 by Dow Jones
  Companies Mentioned: MDGL
  
  Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to those risks and uncertainties discussed in Part I, Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission, or SEC, on February 28, 2024, and Part II, Item 1A of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 7, 2024, and as updated from time to time by Madrigal's other filings with the SEC.. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Madrigal undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Madrigal's submissions filed with the SEC for more detailed information regarding these risks and uncertainties and other factors that may cause actual results to differ materially from those expressed or implied.